KMT2C and essential thrombocythemia: In addition to the group of CML patients, we also investigated the expression profile of MLL2/KMT2D and MLL3/KMT2C genes in other myeloproliferative diseases including polycythemia vera (N = 25), essential thrombocythemia (N = 35) and primary myelofibrosis (N = 20).